SULT1

STAT1 is a latent transcription factor within the JAK-STAT signaling pathway, originally defined through cellular responses to interferons^[1]. Mechanistically, STAT1 connects interferon and cytokine receptor activation to rapid gene-expression programs that regulate host defense, immune signaling, and disease biology^[1][2]. In human immunity, inherited STAT1 defects define autosomal recessive complete deficiency, autosomal recessive partial deficiency, autosomal dominant deficiency, and autosomal dominant gain-of-function disease^[2]. Disease models show that loss-of-function STAT1 variants impair IFN-γ- and IFN-α/β-mediated immunity, whereas gain-of-function variants enhance STAT1-dependent responses and impair IL-17 immunity in chronic mucocutaneous candidiasis^[2][3]. Compared with the full-length STAT1α isoform, STAT1β lacks the C-terminal transactivation domain but is not simply dominant negative in vivo^[4]. Isoform-specific mouse models show that STAT1α and STAT1β have largely redundant IFN-α/β- and IFN-λ-dependent antiviral activity, while STAT1β remains transcriptionally active after IFN-γ stimulation^[4]. In esophageal squamous cell carcinoma models, STAT1β interacts with STAT1α, decreases STAT1α proteasomal degradation, and increases STAT1 DNA binding and transcriptional activity^[5]. Therefore, STAT1 research should distinguish total STAT1 from STAT1α and STAT1β when designing interferon signaling, infection, immunity, or tumor biology studies^[4][5].